Venlafaxine

Generic Name: Venlafaxine

Brand Names: Effexor

Drug Type: Small Molecule

Chemical Formula: C_₁₇H_₂₇NO_₂

CAS Number: 93413-69-5

Unique Ingredient Identifier: GRZ5RCB1QG

Background: Venlafaxine is an antidepressant and a serotonin and norepinephrine reuptake inhibitor (SNRI). Its active metabolite, desvenlafaxine, works by blocking the reuptake of serotonin and norepinephrine, which are key neurotransmitters in mood regulation. Venlafaxine is officially approved to treat major depressive disorder (MDD), generalized anxiety disorder (GAD...

Indication: Venlafaxine is indicated for the management of major depressive disorder (MDD), generalized anxiety disorder (GAD), social anxiety disorder (SAD), and panic disorder.

Associated Conditions: Generalized Anxiety Disorder, Major Depressive Disorder (MDD), Migraine, Neuropathic Pain, Panic Disorder, Social Anxiety Disorder (SAD), Vasomotor Symptoms Associated With Menopause

Associated Therapies: -

Clinical Trials

Neurochemical, Metabonomics and Neuroimaging Characterization of TCM Diagnostic Subtypes of Major Depression Disorder

Phase 4

Conditions: Severe Major Depression Disorder

Interventions: Drug: venlafaxine

First Posted Date: 2015-01-27

Last Posted Date: 2015-04-27

Lead Sponsor: Zhejiang Provincial Tongde Hospital

Target Recruit Count: 75

Registration Number: NCT02346682

Locations: 🇨🇳
Tongde hospital of zhejiang province, Hangzhou, Zhejiang, China

Serotonin-norepinephrine Reuptake Inhibitors and Acute Kidney Injury

Completed

Conditions: Acute Kidney Injury
Depression

Interventions: Drug: Duloxetine
Drug: Citalopram
Drug: Escitalopram
Drug: Venlafaxine
Drug: Desvenlafaxine
Drug: Fluoxetine
Drug: Fluvoxamine
Drug: Paroxetine
Drug: Sertraline

First Posted Date: 2014-12-19

Last Posted Date: 2016-03-14

Lead Sponsor: Canadian Network for Observational Drug Effect Studies, CNODES

Target Recruit Count: 3255526

Registration Number: NCT02320240

Locations: 🇨🇦
Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Quebec, Canada

Incomplete Response in Late-Life Depression: Getting to Remission With Buprenorphine

Phase 1

Completed

Conditions: Depression
Major Depressive Disorder

Interventions: Drug: venlafaxine
Drug: placebo
Drug: buprenorphine

First Posted Date: 2014-10-13

Last Posted Date: 2018-07-26

Lead Sponsor: Centre for Addiction and Mental Health

Target Recruit Count: 56

Registration Number: NCT02263248

Locations: 🇨🇦
Centre for Addiction and Mental Health, Toronto, Ontario, Canada

Optimizing Antidepressant Treatment by Genotype-dependent Adjustment of Medication According to the ABCB1 Gene

Phase 4

Conditions: Major Depression

Interventions: Drug: Paroxetine
Drug: Sertraline
Drug: Citalopram
Drug: Venlafaxine
Drug: Amitriptyline
Drug: Escitalopram
Drug: Amitriptylinoxide
Drug: Nortriptyline
Drug: Trimipramine

First Posted Date: 2014-09-12

Last Posted Date: 2014-09-12

Lead Sponsor: HolsboerMaschmeyer NeuroChemie GmbH

Target Recruit Count: 80

Registration Number: NCT02237937

Locations: 🇩🇪
Max Planck Institute of Psychiatry, Munich, Bavaria, Germany

Antidepressants and Bone Mineral Density

Phase 3

Completed

Conditions: Bone Mineral Density Quantitative Trait Locus 7

Interventions: Drug: sertraline
Drug: citalopram
Drug: venlafaxine
Drug: reboxetine
Behavioral: control

First Posted Date: 2014-07-01

Last Posted Date: 2014-07-01

Lead Sponsor: Guiyang Medical University

Target Recruit Count: 203

Registration Number: NCT02179268

Trazodone Once a Day in Major Depression Disorder

Phase 3

Completed

Conditions: Major Depressive Disorder

Interventions: Drug: Trazodone
Drug: Venlafaxine

First Posted Date: 2014-03-13

Last Posted Date: 2015-12-30

Lead Sponsor: Aziende Chimiche Riunite Angelini Francesco S.p.A

Target Recruit Count: 364

Registration Number: NCT02086929

Locations: 🇨🇿
PRAGTIS, s.r.o., Praha 2, Praha, Czech Republic
🇨🇿
Psychiatry Trial, s.r.o., Praha 5, Praha, Czech Republic
🇷🇴
Quantum Medical Center Srl, Bucharest, Romania

and more 29 locations

Interpersonal Psychotherapy for Treatment Resistant Depression

First Posted Date: 2013-07-11

Last Posted Date: 2013-07-11

Lead Sponsor: Hospital de Clinicas de Porto Alegre

Target Recruit Count: 74

Registration Number: NCT01896349

Locations: 🇧🇷
Federal University of Rio Grande do Sul / Hospital de Clínicas de Porto Alegre (HCPA), Porto Alegre, RS, Brazil

Comparison of Venlafaxine and Fluoxetine in the Treatment of Postmenopausal Women With Major Depression

Phase 4

Completed

Conditions: Major Depression

Interventions: Drug: fluoxetine
Drug: venlafaxine

First Posted Date: 2013-04-04

Last Posted Date: 2017-09-14

Lead Sponsor: Capital Medical University

Target Recruit Count: 189

Registration Number: NCT01824433

Locations: 🇨🇳
Beijing Anding Hospital, Beijing, Beijing, China

Algorithm Guided Treatment Strategies for Major Depressive Disorder

Phase 4

Conditions: Major Depressive Disorder

Interventions: Drug: Escitalopram
Drug: Fluoxetine
Drug: Mirtazapine
Drug: Citalopram
Other: modified electroconvulsive therapy
Other: repetitive transcranial magnetic stimulation
Drug: Paroxetine
Drug: Sertraline
Drug: Fluvoxamine
Drug: Venlafaxine
Drug: Duloxetine
Drug: Bupropion
Drug: Trazodone

First Posted Date: 2013-01-10

Last Posted Date: 2013-01-10

Lead Sponsor: Shanghai Mental Health Center

Target Recruit Count: 1080

Registration Number: NCT01764867

Locations: 🇨🇳
Shanghai Mental Health Center, Shanghai, China

Healing With Venlafaxine After Injury (HELP)

Phase 2

Completed

Conditions: Neck Pain

Interventions: Drug: Venlafaxine

First Posted Date: 2012-10-29

Last Posted Date: 2017-04-13

Lead Sponsor: Rhode Island Hospital

Target Recruit Count: 20

Registration Number: NCT01716377

Locations: 🇺🇸
Spectrum Health, Grand Rapids, Michigan, United States
🇺🇸
University of Rochester Medical Center, Rochester, New York, United States
🇺🇸
University of Cincinnati, Cincinnati, Ohio, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy